撰文丨王聪 编辑丨王多鱼 排版丨水成文 单个细胞发育成胚胎的过程代表了生物学中最深刻的进程之一。无论是植物还是动物，胚胎通常起源于受精卵 （由配子融合形成的全能细胞） 。传统观点认为， 唯有受精卵才具备全能性，即形成完整生物体所需全部细胞类型的能力。 在 植物 中，已分化的体细胞在适宜条件下能重新获得全能性并启动胚胎发生，这种现象被称为 体细胞胚胎发生 。这种非凡能力构成了植物独特再生潜力的基 础，并为研究细胞可塑性与重编程的分子机制提供了宝贵模型。 然而，植物的 体细胞胚胎发生的精确细胞起源，以及使体细胞重获全能性的分子通路，是一个悬而未决的世纪难题。"单个体细胞如何发育成完整植株"，这一问 题早在 2005 年，就被国际顶尖学术期刊 Science 在其创刊 125 周年时列为 最具挑战的 125 个关键科学问题之一 。 2025 年 9 月 16 日， 山东农业大学 张宪省 、 苏英华 及 荷兰拉德堡德大学 须健 、 北京华大生命科学研究院 夏科科 作为共同通讯作者 （ 唐丽苹 、 翟立明 、 李纪明 、 高月 为共同第一作者 ） ，在国际顶尖学术期刊 Cell 上发表了题为 ： Time-resolv ...

Core Insights - Tolremo Therapeutics is a Swiss biotech company founded in 2017, focusing on the development of CBP/p300 bromodomain inhibitors to combat non-genetic cancer drug resistance [2][4][6] - The company has identified a key mechanism governing transcriptional resistance pathways and developed an oral small molecule inhibitor, TT125-802, which targets CBP/p300 [6][8] - Tolremo has completed a $39 million Series A financing round to accelerate the clinical development of TT125-802, which has shown promising preclinical efficacy in combination with targeted therapies for specific advanced tumors [9] Company Overview - Tolremo Therapeutics is a spin-off from ETH Zurich, founded by Stefanie Flückiger-Mangual, who serves as the CEO [2] - The company aims to reverse non-genetic drug resistance in cancer through targeted transcriptional reprogramming [4][7] Product Development - TT125-802 is designed to block the interaction between CBP/p300 and DNA, preventing early transcriptional escape mechanisms in cancer cells [8] - The inhibitor has demonstrated significant clinical activity in preclinical models of non-small cell lung cancer, colorectal cancer, and prostate cancer when used in combination with existing targeted therapies [8] Clinical Trials and Milestones - In November 2023, Tolremo announced the completion of its first human clinical trial for TT125-802, marking a significant milestone in its development [8] - The company plans to continue clinical trials to evaluate the efficacy of TT125-802 in combination with targeted therapies for specific advanced tumors, including those with EGFR and KRAS mutations [9] Recognition and Innovation - Tolremo Therapeutics was listed in the 2024 TOP100 Swiss Startups, highlighting its status as one of the most innovative and promising companies in Switzerland [11]